ONCOCYTE CORP (OCX)

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study...

OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024

OCX stock results show that OncoCyte beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips OncoCyte (NASDAQ:OCX) just reported results for the second quarter of 2024.Onco...

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

Oncocyte Announces Successful GraftAssureTM Beta Launch and Q2 2024 Results...

Oncocyte Announces August Investor Conferences Participation

Oncocyte Announces August Investor Conferences Participation...

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8...

Oncocyte Appoints Andrea James as Chief Financial Officer

Oncocyte Appoints Seasoned Finance Executive Andrea James as Chief Financial Officer...

OncoCyte’s (NASDAQ:OCX) Innovative Approach: Potential in Precision Diagnostics

OncoCyte's Innovative Approach: Potential in Precision Diagnostics

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects.

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and...

OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024

OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips OncoCyte (NASDAQ:OCX) just reported results for the first quarter of 2024.OncoC...

Oncocyte Reports First Quarter 2024 Financial Results

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!

OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023

OCX stock results show that OncoCyte missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!

Oncocyte Reports Full Year 2023 Financial Results

ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS...

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules...

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay...

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS...

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE,...

Oncocyte Reports Third Quarter 2023 Financial Results

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 ...

Oncocyte to Announce Third Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ...

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper...

Oncocyte Announces 1-For-20 Reverse Stock Split

IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today...